Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression

NCT04178798 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT04178798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04178798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression
Lead sponsor
PETHEMA Foundation
Phase
Phase 3
Overall status
Completed
Start date
December 9, 2019
Completion date
December 3, 2024
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia- binet staging system